Replimune Group (REPL)
(Delayed Data from NSDQ)
$3.46 USD
-2.25 (-39.40%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $3.47 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.89 | 0.00% |
Earnings Summary
For their last quarter, Replimune Group (REPL) reported earnings of -$0.95 per share, missing the Zacks Consensus Estimate of -$0.83 per share. This reflects a negative earnings surprise of 14.46%. Look out for REPL's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.89 per share, reflecting a year-over-year decrease of 30.88%.
Earnings History
Price & Consensus
Zacks News for REPL
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
REPL FAQs
Based on past history, Zacks believes Replimune Group, Inc. (REPL) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.89 per share, reflecting a year-over-year increase of -30.88.
Based on past history, Zacks believes Replimune Group, Inc. (REPL) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Replimune Group, Inc. (REPL) for the quarter ending September 2025 is $-0.89 a share. We expect Replimune Group, Inc. (REPL) to report earnings in line with the consensus estimate of $-0.89 per share
In the earnings report for the quarter ending in June 2024, Replimune Group, Inc. (REPL) announced earnings of $-0.78 per share versus the Zacks Consensus Estimate of $-0.88 per share, representing a surprise of -11.36%.